financetom
Business
financetom
/
Business
/
L3harris Technologies Insider Sold Shares Worth $11,472,333, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
L3harris Technologies Insider Sold Shares Worth $11,472,333, According to a Recent SEC Filing
Jun 5, 2024 12:37 AM

03:20 AM EDT, 06/05/2024 (MT Newswires) -- Christopher E Kubasik, Director, Chair and Chief Executive Officer, on May 31, 2024, sold 51,190 shares in L3harris Technologies ( LHX ) for $11,472,333. Following the Form 4 filing with the SEC, Kubasik has control over a total of 159,304 shares of the company, with 120,326 shares held directly and 38,978 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/202058/000020205824000113/xslF345X03/wk-form4_1717541825.xml

Price: 227.00, Change: +0.31, Percent Change: +0.14

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Moderna Tightens 2025 Revenue Outlook as Third-Quarter Top-Line Beats Estimates
Moderna Tightens 2025 Revenue Outlook as Third-Quarter Top-Line Beats Estimates
Nov 6, 2025
10:37 AM EST, 11/06/2025 (MT Newswires) -- Moderna ( MRNA ) narrowed its full-year revenue outlook on Thursday as the drugmaker's third-quarter top-line declined less than expected amid weak COVID-19 vaccine sales. The company now anticipates revenue to come in between $1.6 billion and $2 billion for 2025, compared with its previous guidance of $1.5 billion to $2.2 billion. The...
Medicenna's MDNA-11 to Be Tested With Immunotherapies in Italian Melanoma Trial
Medicenna's MDNA-11 to Be Tested With Immunotherapies in Italian Melanoma Trial
Nov 6, 2025
10:36 AM EST, 11/06/2025 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) said Thursday its lead candidate MDNA-11 is being tested with two major immunotherapies in an Italian clinical trial. The trial, Neo-Cyt, involves patients with high-risk, surgically resectable Stage III cutaneous melanoma and is sponsored by the non-profit Melanoma Foundation at the National Cancer Institute's G. Pascale Foundation in...
UroGen Says FDA Agrees to New Drug Application for UGN-103 Based on Phase 3 Data
UroGen Says FDA Agrees to New Drug Application for UGN-103 Based on Phase 3 Data
Nov 6, 2025
10:36 AM EST, 11/06/2025 (MT Newswires) -- UroGen Pharma ( URGN ) said Thursday that the US Food and Drug Administration has agreed that the preliminary complete response rate and durability results from an ongoing phase 3 trial of UGN-103 in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer can support the submission of a new drug application. Initial results from...
Form 8.3
Form 8.3
Nov 6, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved